Therapeutic Solutions to use immunotherapy for COVID-19

By The Science Advisory Board staff writers

Therapeutic Solutions plans to develop its clinical stage cancer immunotherapy treatment StemVacs for treatment of COVID-19 patients.

The company has filed a patent on its StemVacs dendritic cell therapy for boosting COVID-19 immunity, it said. The patent describes how StemVacs prompts the body to boost activity of "natural killer" immunological cells, which have been shown to inhibit SARS-CoV-2.

StemVacs is being developed both as standalone immunotherapy as well as an adjuvant product to improve the efficacy of stimulators of the adaptive immune responses, according to Therapeutic Solutions. The ability to supercharge dendritic cells provides a unique virology approach to fighting COVID-19.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?